407 related articles for article (PubMed ID: 11298329)
1. Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1.
Nilsson-Ekdahl K; Nilsson B
Eur J Immunol; 2001 Apr; 31(4):1047-54. PubMed ID: 11298329
[TBL] [Abstract][Full Text] [Related]
2. Alterations in C3 activation and binding caused by phosphorylation by a casein kinase released from activated human platelets.
Ekdahl KN; Nilsson B
J Immunol; 1999 Jun; 162(12):7426-33. PubMed ID: 10358196
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of complement component C3 and C3 fragments by a human platelet protein kinase. Inhibition of factor I-mediated cleavage of C3b.
Ekdahl KN; Nilsson B
J Immunol; 1995 Jun; 154(12):6502-10. PubMed ID: 7539023
[TBL] [Abstract][Full Text] [Related]
4. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.
Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ
J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880
[TBL] [Abstract][Full Text] [Related]
5. Factor I co-factor activity of CR1 overcomes the protective effect of IgG on covalently bound C3b residues.
Fries LF; Prince GM; Gaither TA; Frank MM
J Immunol; 1985 Oct; 135(4):2673-9. PubMed ID: 3161945
[TBL] [Abstract][Full Text] [Related]
6. Activation, binding, and processing of complement component 3 (C3) by Blastomyces dermatitidis.
Zhang MX; Klein B
Infect Immun; 1997 May; 65(5):1849-55. PubMed ID: 9125571
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
[TBL] [Abstract][Full Text] [Related]
8. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
Sahu A; Isaacs SN; Soulika AM; Lambris JD
J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
[TBL] [Abstract][Full Text] [Related]
9. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
Newman SL; Mikus LK
J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
[TBL] [Abstract][Full Text] [Related]
10. Dissection of CR1, factor H, membrane cofactor protein, and factor B binding and functional sites in the third complement component.
Lambris JD; Lao Z; Oglesby TJ; Atkinson JP; Hack CE; Becherer JD
J Immunol; 1996 Jun; 156(12):4821-32. PubMed ID: 8648130
[TBL] [Abstract][Full Text] [Related]
11. Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.
Kozel TR; Wilson MA; Pfrommer GS; Schlageter AM
Infect Immun; 1989 Jul; 57(7):1922-7. PubMed ID: 2525113
[TBL] [Abstract][Full Text] [Related]
12. Common binding region of complement factors B, H and CR1 on C3b revealed by monoclonal anti-C3d.
Koistinen V; Wessberg S; Leikola J
Complement Inflamm; 1989; 6(4):270-80. PubMed ID: 2527715
[TBL] [Abstract][Full Text] [Related]
13. Effect of antigen site and complement receptor status on the rate of cleavage of C3c antigen from red cell bound C3b.
Currie MS; Rustagi PK; Wojcieszak R; Ziolkowski L; Ross GD; Logue GL
Blood; 1988 Mar; 71(3):786-90. PubMed ID: 3345346
[TBL] [Abstract][Full Text] [Related]
14. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
Mayes JT; Schreiber RD; Cooper NR
J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
[TBL] [Abstract][Full Text] [Related]
15. The attachment of serum- and plasma-derived C3 to solid-phase immune aggregates and its relation to complement-mediated solubilization of immune complexes.
Baatrup G; Svehag SE; Jensenius JC
Scand J Immunol; 1986 Apr; 23(4):397-406. PubMed ID: 3486458
[TBL] [Abstract][Full Text] [Related]
16. Regulatory proteins for the activated third and fourth components of complement (C3b and C4b) in mice. II. Identification and properties of complement receptor type 1 (CR1).
Kinoshita T; Lavoie S; Nussenzweig V
J Immunol; 1985 Apr; 134(4):2564-70. PubMed ID: 3156184
[TBL] [Abstract][Full Text] [Related]
17. Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification.
Jelezarova E; Vogt A; Lutz HU
Biochem J; 2000 Jul; 349(Pt 1):217-23. PubMed ID: 10861231
[TBL] [Abstract][Full Text] [Related]
18. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes.
Medof ME; Iida K; Mold C; Nussenzweig V
J Exp Med; 1982 Dec; 156(6):1739-54. PubMed ID: 7175439
[TBL] [Abstract][Full Text] [Related]
19. Reduced erythrocyte CR1 (CD 35) receptor function and complement opsonization in factor I-deficient patients is restored by plasma infusion.
Jepsen HH; Teisner B; Rasmussen JM; Svehag SE
Scand J Immunol; 1989 Feb; 29(2):247-55. PubMed ID: 2522236
[TBL] [Abstract][Full Text] [Related]
20. Inefficient binding of IgM immune complexes to erythrocyte C3b-C4b receptors (CR1) and weak incorporation of C3b-iC3b into the complexes.
Kávai M; Rasmussen JM; Baatrup G; Zsindely A; Svehag SE
Scand J Immunol; 1988 Jul; 28(1):123-8. PubMed ID: 2969612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
